Assoc. Prof. Dr. Halil Ibrahim Erdoğdu - infectious diseases - Excellence in Research

Kafkas University - Turkey

Author Profile

🎓 Early academic pursuits

Halil Ibrahim Erdoğdu began his journey in medicine at dicle university faculty of medicine, where he studied from 1985 to 1991. after graduating in 1991, he pursued specialization in internal medicine between 1994 and 1998. his early academic focus laid the foundation for his future contributions to internal medicine, nephrology, and immunology, drawing interdisciplinary parallels with advanced technological systems like power electronics, emphasizing precision and control in medical interventions.

🏥 Professional endeavors

Following his specialization, dr. erdoğdu served at kars state hospital from 1998 to 2015, significantly impacting regional healthcare. since 2015, he has been a dedicated clinician and educator at the internal medicine clinic of kafkas university. his clinical excellence is paired with responsibilities as the statistics editor for the kafkas journal of medical sciences, showcasing his dual focus on patient care and academic quality, much like the regulated flow in power electronics systems ensuring efficiency and stability.

🔬 Contributions and research focus

Dr. Erdoğdu’s research concentrates on immunology, hemodialysis, and infectious diseases. his notable studies include the evaluation of vaccine responses in hemodialysis patients and elderly populations, such as the investigation into the level of response to covid-19 vaccine in hemodialysis patients. these studies aim to enhance public health through data-driven insights, infectious diseases integrating methodologies akin to diagnostic precision in power electronics—optimizing performance through feedback mechanisms and individual-based adaptation.

🌍 Impact and influence

With publications in renowned journals such as clinical and experimental nephrology, heart lung and circulation, and current microbiology, dr. erdoğdu's work has influenced both national and international academic communities. his research on vaccine efficacy and public awareness contributes significantly to patient education and public health planning, especially in high-risk infectious diseases groups like the elderly and those undergoing dialysis.

📚 Academic citations

Dr. Erdoğdu’s scientific contributions are reflected in his academic impact, with an h-index of 6 and i-10 index of 5 according to google scholar. his scopus author profile (id: 57190609988) also infectious diseases confirms a solid record of peer-reviewed research, further affirming his role in advancing internal medicine research.

🛠️ Legacy and future contributions

With several published books (isbn: 978-625-8065-78-7, 978-625-8324-24-2, among others) and continuing engagement in research, dr. erdoğdu is committed to mentoring new professionals and enhancing the scientific community’s understanding of immunological responses and chronic disease management. his future work is expected to integrate more translational research, further linking theoretical knowledge with practical application in clinical settings.

Notable Publications

Title: Can complete blood cell count parameters predict deep vein thrombosis? / Mogu li parametri kompletne krvne slike predvidjeti duboku vensku trombozu?
Authors: Tural, K.; Kara, F.; Avcı, S.; Erdoğdu, H.İ.
Journal: Acta Clinica Croatica (2020)
Title: Factors affecting inadequate response to HBV vaccine in hemodialysis patients: northeast Anatolia survey with six hemodialysis centers
Authors: Erdoğdu, H.İ.; Atalay, E.; Gürsoy, G.; Canbakan, B.; Aktürk, S.; Yazıcı, C.; Yücel, O.; Mersin, S.; Üçer, S.; Merhametsiz, Ö. et al.
Journal: Clinical and Experimental Nephrology (2019)
Title: Hypoalbuminemia and related factors in hemodialyzed patients: A study of six centers in Turkey / Hemodiyaliz hastalarında hipoalbüminemi ve ilişkili faktörler: Türkiye’de altı merkezli bir çalışma
Authors: Erdoğdu, H.İ.; Atalay, E.
Journal: Haseki Tip Bulteni (2019)
Title: The C-Reactive Protein to Albumin Ratio Predicts Acute Kidney Injury in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Authors: Karabağ, Y.; Çağdaş, M.; Rencuzogullari, I.; Karakoyun, S.; Artaç, İ.; İliş, D.; Yesin, M.; Çiftçi, H.; Erdoğdu, H.I.; Tanboğa, I.H.
Journal: Heart Lung and Circulation (2019)
Title: The relationship between C-reactive protein/albumin ratio and 1-year mortality in hospitalized elderly COPD patients with acute exacerbation / Akut KOAH atağı ile hastaneye yatırılan yaşlı hastalarda 1 yıl mortalite ile C-reaktif protein/albumin oranı arasındaki ilişkinin değerlendirilmesi
Authors: Atalay, E.; Erdoğdu, H.İ.; Tur, B.K.; Deniz Balyen, L.S.; Karabağ, Y.; Ardiç, S.
Journal: Turk Geriatri Dergisi (2019)

🎓 EARLY ACADEMIC PURSUITS

WenQing Yang, Ph.D., embarked on a distinguished academic journey that laid the foundation for his influential career in biomedical research. His early education was marked by a profound interest in understanding complex biological systems, which guided him through rigorous academic training. Dr. Yang’s academic pursuits provided him with a robust understanding of animal disease modeling and cancer pharmacology, paving the way for his future contributions in these fields.

💼 PROFESSIONAL ENDEAVORS

With over 30 years of experience, Dr. Yang has made significant strides in drug discovery and development. His professional career began with a focus on early-stage drug discovery, where he demonstrated exceptional skill in advancing drug candidates from discovery to clinical development. Dr. Yang's career spans roles in both large pharmaceutical companies and small biotech firms, showcasing his versatility and leadership. His tenure as Founder and Chief Scientific Officer at Clinbridge Biotech Co. Ltd has been pivotal in establishing the company’s research and discovery infrastructure, driving scientific programs, and fostering global collaborations.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Yang’s research has been instrumental in the areas of cancer pharmacology, immuno-oncology, and autoimmune diseases. His work encompasses a wide range of activities, from animal disease modeling and cancer immunotherapy discovery to novel therapeutic targets validation. Dr. Yang’s expertise in dissecting the tumor micro-environment and validating biomarkers has led to significant advancements in understanding and treating complex diseases. His contributions to translational research have been crucial in bridging the gap between Translational preclinical modelling for cancer and autoimmune diseases preclinical studies and clinical applications.

🏆 ACCOLADES AND RECOGNITION

Throughout his career, Dr. Yang has been recognized for his exceptional contributions to biomedical research and drug discovery. His leadership in advancing over 20 drug candidates to PCC nomination or IND filing, with 15 molecules progressing to clinical trials, highlights his impact on the field. His role in leading translational sciences at Simcere Pharma Group Ltd further solidified his reputation as a leader in drug development and Translational preclinical modelling for cancer and autoimmune diseases translational research.

🌍 IMPACT AND INFLUENCE

Dr. Yang’s influence extends globally, with his research impacting both academic and clinical settings. His efforts in advancing drug discovery and development have led to innovative therapeutic approaches in oncology and immuno-oncology. By establishing and leading scientific programs Translational preclinical modelling for cancer and autoimmune diseases at Clinbridge Biotech and Simcere Pharma, Dr. Yang has played a crucial role in shaping the future of drug discovery and translational medicine, driving forward new treatments and therapeutic strategies.

🏛️ LEGACY AND FUTURE CONTRIBUTIONS

Dr. Yang’s legacy is characterized by his dedication to advancing biomedical research and drug discovery. His work has set new standards in cancer pharmacology, immuno-oncology, and autoimmune diseases. Looking ahead, Dr. Yang is poised to continue his impactful work, focusing on novel therapeutics and innovative research approaches. His commitment to scientific excellence and leadership will undoubtedly inspire future advancements in the field, ensuring that his contributions continue to benefit the biomedical community for years to come.